Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS
The employment of Ramona Doyle, MD as chief medical officer ("CMO") of Recursion
Pharmaceuticals, Inc. (the "Company") ended on June 7, 2022.
Also, on June 7, 2022, the Company appointed Shafique Virani, MD FRCS, as
interim CMO. Dr. Virani continues to also serve as the Company's chief business
officer. Dr. Virani joined the Company in March 2020 and served as its interim
CMO until December 2020. Since December 2020, he has served as the Company's
chief business officer. Prior to joining the Company, from 2017 to 2019,
Dr. Virani served as the chief executive officer of two subsidiaries of
BridgeBio LLC, Navire Pharma and CoA Therapeutics, and before that held senior
roles in business development at Roche and Genentech from 2006 to 2017.
Dr. Virani also served as a medical director at Roche from 2004 to 2006 in the
United Kingdom. Dr. Virani holds an M.D. from the University of Nottingham and
trained in neurosurgery at Cambridge, UK, and Boston.
There are no arrangements or understandings required to be disclosed pursuant to
Item 401(b) of Regulation S-K or family relationships required to be disclosed
pursuant to Item 401(d) of Regulation S-K. There are no transactions with
related persons required to be disclosed pursuant to Item 404(a) of Regulation
S-K involving Dr. Virani.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
RECURSION PHARMACEUTICALS, INC. 
